Substantially Improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO). An international randomized phase III trial

Autor: A Jager, M Jongen-Lavrencic, JP Lotz, A Gonçalves, M Graeser, U Nitz, IAM Mandjes, MJ Holtkamp, M Schot, VP Retel, EJ Kuip, ANM Wymenga, IR Konings, VCG Tjan-Heijnen, JR Kroep, CP Schrӧder, E Van Der Wall, Sc Linn, S Vliek

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3389d18e6873ca9ee30fb022f95fc593

[Long-term beneficial effects of cetuximab in a woman with metastasised rectal carcinoma without expression of the epidermal growth factor receptor]

Autor: Jr, Kroep, Hans Gelderblom, Af, Collen, Jw, Nortier

Publikováno v: Europe PubMed Central

A 37-year-old woman presented with an epidermal growth factor-(EGFR)-negative rectum carcinoma with liver metastases. After extensive treatment, consisting of first-line chemotherapy, low anterior resection, isolated liver perfusion, second- and thir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6c0f0bb6d096fc69663d529be44013ef
http://europepmc.org/abstract/med/17152334

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

Autor: de Azambuja E; Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Service d'oncologie médicale, Brussels. Electronic address: evandro.deazambuja@hubruxelles.be., Piccart-Gebhart M; Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium., Fielding S; Frontier Science (Scotland) Ltd., Kincraig, UK., Townend J; Frontier Science (Scotland) Ltd., Kincraig, UK., Hillman DW; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USA., Colleoni M; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Roylance R; Department of Oncology, UCLH Foundation Trust, London, UK., Kelly CM; Cancer Trials Ireland, Dublin, Ireland; Mater Private Hospital, Dublin, Ireland., Lombard J; Breast Cancer Trials (Australia New Zealand), Newcastle, Australia., El-Abed S; Breast International Group (BIG), Brussels, Belgium., Choudhury A; Novartis Healthcare Pvt Ltd, Hyderabad, India., Korde L; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA., Vicente M; Institut Jules Bordet, Brussels, Belgium., Chumsri S; Mayo Clinic, Jacksonville, USA., Rodeheffer R; Mayo Clinic College of Medicine and Science, Rochester, USA., Ellard SL; BC Cancer Kelowna, Kelowna, Canada., Wolff AC; The Johns Hopkins Kimmel Cancer Center, Baltimore, USA., Holtschmidt J; German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany., Lang I; Clinexpert Research, Gyongyos, Hungary., Untch M; Helios Klinikum Berlin-Buch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Breast Cancer Center, Berlin, Germany; AGO B Study Group, Study Center of the Women's Clinic, Erlangen University Hospital, Erlangen, Germany., Boyle F; Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, North Sydney, Australia; University of Sydney, Sydney, Australia., Xu B; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Werutsky G; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Tujakowski J; Chemotherapy, Centre of Oncology, Bydgoszcz, Poland., Huang CS; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Baruch NB; Holy Family Hospital, Nazareth, Israel., Bliss J; The Institute of Cancer Research, London, UK., Ferro A; Breast Unit, Department of Medical Oncology, APSS, Trento, Italy., Gralow J; American Society of Clinical Oncology, Alexandria, USA., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kroep JR; Leiden University Medical Center, Leiden, The Netherlands., Krop I; Yale Cancer Center, New Haven, Connecticut, USA., Kuemmel S; Breast Unit, Kliniken Essen-Mitte, Essen; Clinic for Gynecology with Breast Center, Charité-Universitätsmedizin, Berlin, Germany., McConnell R; Frontier Science (Scotland) Ltd., Kincraig, UK., Moscetti L; Department of Oncology-Hematology, University Hospital of Modena, Modena; GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy., Knop AS; Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark., van Duijnhoven F; Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Gomez H; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru., Cameron D; Edinburgh University Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Di Cosimo S; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Gelber RD; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, Boston; Frontier Science Foundation, Boston, USA., Moreno-Aspitia A; Mayo Clinic, Jacksonville, USA.

Publikováno v: ESMO open [ESMO Open] 2024 Oct 16; Vol. 9 (11), pp. 103938. Date of Electronic Publication: 2024 Oct 16.

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.

Autor: Azim HA Jr; Cairo Cure Oncology Center, Cairo, Egypt.; Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico., Niman SM; International Breast Cancer Study Group Statistical Center, Boston, MA.; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Demeestere I; Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium.; Gynecology and Obstetrics Department, Fertility Clinic, HUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium., Ruggeri M; Program for Young Patients, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland., Colleoni M; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain., Shimizu C; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Saetersdal AB; Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; Dutch Breast Cancer Research Group (BOOG), Amsterdam, the Netherlands., Mailliez A; Breast Cancer Unit, Department of Medical Oncology, Centre Oscar Lambret, Lille, France., Warner E; Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, ON, Canada.; Canadian Clinical Trials Group (CCTG), Toronto, ON, Canada., Borges VF; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO., Amant F; Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium.; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium.; Antoni van Leeuwenhoek-Netherlands Gynecologic Oncology Cancer Institute, Amsterdam, the Netherlands., Gombos A; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium., Kataoka A; Breast Oncology Cancer, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Rousset-Jablonski C; Department of Surgery, Leon Berard Cancer Centre, Centre Léon Bérard, Lyon, France., Borstnar S; Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia., Takei J; St Luke's International Hospital, Breast Center, Tokyo, Japan., Lee JE; Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.; Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea., Walshe JM; Cancer Trials Ireland, Dublin, Ireland.; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.; Tallaght University Hospital, Dublin, Ireland., Ruíz-Borrego M; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Hospital Virgen del Rocio Sevilla, Sevilla, Spain., Moore HCF; Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Saunders C; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia.; Royal Melbourne Hospital, Melbourne, VIC, Australia., Bjelic-Radisic V; Breast Unit, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany.; Medical University Graz, Department Gynaecology, Graz, Austria.; Austrian Breast and Colorectal Study Group (ABCSG), Vienna, Austria., Susnjar S; Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Cardoso F; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal., Klar NJ; New York University Langone's Perlmutter Cancer Center, Breast Cancer Center, New York, NY., Spanic T; Europa Donna, Ljubljana, Slovenia., Ruddy K; Department of Oncology, Mayo Clinic, Rochester, MN., Piccart M; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium., Korde LA; Breast and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Goldhirsch A; International Breast Cancer Study Group, Division of ETOP IBCSG Partners Foundation, Bern, Switzerland.; IEO, European Institute of Oncology, IRCCS, Milan, Italy., Gelber RD; International Breast Cancer Study Group Statistical Center, Boston, MA.; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Frontier Science Foundation, Boston, MA.; Harvard TH Chan School of Public Health, Boston, MA., Pagani O; Geneva University Hospitals, Geneva, Switzerland.; Lugano University, Lugano, Switzerland.; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Peccatori FA; Fertility and Procreation Unit, Gynecologic Oncology Program, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 10; Vol. 42 (23), pp. 2822-2832. Date of Electronic Publication: 2024 May 29.

PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.

Autor: Westermann A; Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands a.m.westermann@amsterdamumc.nl., Ottevanger P; Dutch Gynaecological Oncology Group (DGOG) and Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Reyners A; University Medical Center Groningen (UMCG), Groningen, The Netherlands., Kroep JR; DGOG and Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, The Netherlands., Van Oijen MGH; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands., Lalisang R; Internal Medicine/Medical Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Witteveen PO; Department of Oncology, University Medical Center, Utrecht, The Netherlands.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Feb 05; Vol. 34 (2), pp. 239-243. Date of Electronic Publication: 2024 Feb 05.